The facility will be fully integrated with a process development lab, quality control and analytical development capabilities, pilot production suite, and current good manufacturing practice (cGMP) production infrastructure. A 2,000-L bioreactor will be used to manufacture gene therapies using a scalable suspension cell culture manufacturing process.

The pilot production suite is set to be online in the first half of 2021 and the full cGMP production facility is set to be online in the second half of 2021.

Taysha gets $95M in financing to advance gene therapies
Taysha Gene Therapies has closed on $95 million in series B financing to advance gene therapies for monogenic central nervous system diseases.

Avantor expands its innovation center for bioprocessing
Avantor is increasing its investment in bioprocessing infrastructure by expanding its innovation center in Bridgewater, NJ.

Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.

Thermo Fisher to double viral vector manufacturing capacity
Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site...